{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-073967","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.478320+00:00","generated_at":"2026-05-17T21:02:25.228640+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nuvectis reports Q2 net loss of $6.3M; NXP900 Phase 1a complete; cash ~$39M proforma","bullets":["Net loss of $6.3M for Q2 2025 vs $4.4M for Q2 2024; increase driven by NXP900 DDI study and stock-based compensation.","Cash and equivalents $26.8M at June 30; after July ATM from healthcare investor, proforma ~$39M; expected to fund into 2H 2027.","NXP900 becomes lead candidate; Phase 1a dose escalation and DDI study completed; Phase 1b program initiation imminent.","NXP800 exploring opportunities in endometrial and prostate cancer; updates expected in coming months.","R&D expenses $3.6M (incl. $1.8M stock-based comp); G&A $3.0M (incl. $1.8M stock-based comp) for Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-073967","json":"https://secwatch.observer/filing/0001104659-25-073967.json","markdown":"https://secwatch.observer/filing/0001104659-25-073967.md","text":"https://secwatch.observer/filing/0001104659-25-073967.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465925073967/0001104659-25-073967-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465925073967/tm2522415d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:02:25.228640+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}